AnaptysBio Inc
NASDAQ:ANAB

Watchlist Manager
AnaptysBio Inc Logo
AnaptysBio Inc
NASDAQ:ANAB
Watchlist
Price: 22.56 USD 7.94% Market Closed
Market Cap: 667.1m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

ANAB Price Targets Summary
AnaptysBio Inc

Wall Street analysts forecast ANAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ANAB is 38.15 USD with a low forecast of 18.18 USD and a high forecast of 59.85 USD.

ANAB Lowest Forecast
Wall Street Target
18.18 USD
19% Downside
ANAB Average Forecast
Wall Street Target
38.15 USD
69% Upside
ANAB Highest Forecast
Wall Street Target
59.85 USD
165% Upside
Lowest
Price Target
18.18 USD
19% Downside
Average
Price Target
38.15 USD
69% Upside
Highest
Price Target
59.85 USD
165% Upside
AnaptysBio Inc Competitors:
Price Targets
IVA
Inventiva SA
206% Upside
E
1952
Everest Medicines Ltd
21% Upside
ITOS
Iteos Therapeutics Inc
154% Upside
RNA
Avidity Biosciences Inc
115% Upside
IVA
Inventiva SA
206% Upside
E
1952
Everest Medicines Ltd
21% Upside
ITOS
Iteos Therapeutics Inc
154% Upside
RNA
Avidity Biosciences Inc
115% Upside
IMTX
Immatics NV
186% Upside
IMNM
Immunome Inc
170% Upside
BBIO
BridgeBio Pharma Inc
81% Upside
SLNO
Soleno Therapeutics Inc
42% Upside

Revenue
Forecast

Revenue Estimate
AnaptysBio Inc

For the last 8 years the compound annual growth rate for AnaptysBio Inc's revenue is 24%. The projected CAGR for the next 3 years is -10%.

24%
Past Growth
-10%
Estimated Growth
Estimates Accuracy
12%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
AnaptysBio Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
AnaptysBio Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-20%
Average Miss
What are analyst estimates?

See Also

Summary
ANAB intrinsic value, competitors valuation, and company profile.
DCF Valuation
ANAB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ANAB stock valuation using valuation multiples.
Wall Street Estimates
ANAB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ANAB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ANAB's stock price target?
Price Target
38.15 USD

According to Wall Street analysts, the average 1-year price target for ANAB is 38.15 USD with a low forecast of 18.18 USD and a high forecast of 59.85 USD.

What is AnaptysBio Inc's Revenue forecast?
Projected CAGR
-10%

For the last 8 years the compound annual growth rate for AnaptysBio Inc's revenue is 24%. The projected CAGR for the next 3 years is -10%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.